Corporate GovernanceJun 17, 2026, 04:12 PM
Madrigal Stockholders Approve 2026 Stock & ESPP; Board Adopts Deferred Comp Plan
AI Summary
Madrigal Pharmaceuticals' stockholders approved the 2026 Stock Plan and the 2026 Employee Stock Purchase Plan at the Annual Meeting on June 17, 2026. Additionally, the Board of Directors adopted a new Nonqualified Deferred Compensation Plan on June 16, 2026, effective August 1, 2026, for key management and non-employee directors. This plan allows pre-tax deferrals of salary, bonuses, fees, and equity. Separately, Dr. Rebecca Taub will transition from an employee to a consultant, providing scientific and medical guidance for the company's MASH programs, effective July 1, 2026.
Key Highlights
- Madrigal Pharmaceuticals stockholders approved the 2026 Stock Plan on June 17, 2026.
- Stockholders also approved the 2026 Employee Stock Purchase Plan (ESPP) at the Annual Meeting.
- The Board approved a Nonqualified Deferred Compensation Plan on June 16, 2026, effective August 1, 2026.
- The Deferred Compensation Plan is for certain key management and non-employee directors.
- Employees can defer up to 60% of base salary and 95% of annual cash performance bonus.
- Non-employee directors can defer cash Board service fees and equity grants.
- Dr. Rebecca Taub will transition from an employee to a consultant effective July 1, 2026.
- Dr. Taub will provide scientific and medical guidance for the company's MASH programs.
Price Impact
More from MDGL